You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
High-specificity affinity reagents for N-glycosylation site mapping and glycomics
SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC Topic: 300DESCRIPTION Glycans have several distinct properties that make them excellent targets for disease biomarkers Firstly the location of the glycans on the cell surface makes them the first point of contact of cellular interactions and thus crucial in the control of normal metabolic processes Cell surface molecules are also strategically exposed for surveillance by the immune system allowing for ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
A new radiopharmaceutical for the treatment of metastatic bone cancer
SBC: IsoTherapeutics Group LLC Topic: NCIDESCRIPTION provided by applicant There are roughly new cases of metastatic cancer to the skeleton in the U S each year andquot Bone seekingandquot radiopharmaceuticals are used for bone pain palliation and have shown promise for treating bone metastases They typically combine a radioactive metal such as samarium with a chelant The chelant part of the molecule is taken up by gr ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Stimulating Young Neuroscientists And Physiologists in Science Education- Phase
SBC: IS3D LLC Topic: 101DESCRIPTION provided by applicant This project will develop a suite of innovative learning experiences that will engage high school students in neuroscience and thereby increase their interest in possible careers in this area This will be achieved by creating highly interactive and immersive products developed in partnership with neuroscience experts science teachers and science education re ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
An Automated Platform for High-throughput Network Electrophysiology
SBC: Axion Biosystems, Inc. Topic: 102DESCRIPTION provided by applicant In response to the program announcement for Phase IIb proposals for complex in vitro brain and behavior tools PA this proposed study automates all aspects of in vitro Microelectrode Array MEA technology to deliver the first ever high throughput MEA based screening system This development will not only enable rapid advancements in the study of basi ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Biomarker Quantitation by NP-MS Tissue Imaging.
SBC: IONWERKS INC Topic: NIDADESCRIPTION provided by applicant MALDI tissue imaging when enabled by Nanoparticulate NP Matrix implantation is maturing into a useful preclinical tool for biomarker and drug discovery in our laboratory and at NIDA IRP Quantitatively reproducible images from serial coronal sections suggest that relative quantitation is now possible in rodent models of disease and injury Nanoparticulate ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Long-Acting G-CSF Analog for Treating ARS
SBC: BOLDER BIOTECHNOLOGY INC Topic: NIAIDDESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF
SBC: SAVARA INC. Topic: NHLBIDESCRIPTION provided by applicant Persistent respiratory methicillin resistant Staphylococcus aureus MRSA infections have become increasingly common in cystic fibrosis CF patients with a prevalence of almost in CF patients in the US This is concerning as MRSA positivity is associated with a faster decline of lung function and a years shorter median life expectancy compared to CF p ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Orally Active Formulations of DHA Dimers for the Treatment of Infectious Diseases
SBC: ElSohly Laboratories, Incorporated Topic: NIAIDDESCRIPTION (provided by applicant): The natural product artemisinin is a sesquiterpene endoperoxide with known anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant strains of the parasite Plasmodium falciparum. In addition to its anti-malarial activity, artemisinin was reported to have cytotoxic activity against several different tumor cell lines. Recently, artemisi ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Biomarker discovery for immunodiagnosis of invasive candidiasis
SBC: DXDISCOVERY INC Topic: NIAIDDESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity
SBC: INVENUX, LLC Topic: NCCAMDESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health